Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aplindore. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 9/20 | 0.60 |
| ▸ | DRD4 | P21917 | 4/20 | 0.60 |
| ▸ | DRD3 | P35462 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HTR2A | P28223 | 3/20 | 0.42 |
| ▸ | HTR2B | P41595 | 3/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aplindore SCHEMBL5954695 | 1.00 | DRD2 (0.60) | DRD2DRD4DRD3MEN1KMT2A | |
| Aplindore SCHEMBL1231153 | 1.00 | DRD2 (0.60) | DRD2DRD4DRD3MEN1KMT2A | |
| Aplindore SCHEMBL3192098 | 0.93 | DRD2 (0.68) | DRD2DRD4DRD3MEN1KMT2A | |
| Aplindore SCHEMBL119499 | 0.93 | DRD2 (0.68) | DRD2DRD4DRD3MEN1KMT2A | |
| Aplindore SCHEMBL29359212 | 0.93 | DRD2 (0.68) | DRD2DRD4DRD3MEN1KMT2A | |
| SCHEMBL5957109 | 0.84 | DRD2 (0.58) | DRD2DRD4DRD3MEN1KMT2A | |
| Aplindore SCHEMBL3029385 | 0.84 | DRD2 (0.54) | DRD2DRD4DRD3MEN1KMT2A | |
| SCHEMBL5957081 | 0.84 | DRD2 (0.55) | DRD2DRD4DRD3MEN1KMT2A | |
| SCHEMBL5957139 | 0.84 | DRD2 (0.55) | DRD2DRD4DRD3MEN1KMT2A | |
| SCHEMBL13481964 | 0.81 | DRD2 (0.52) | DRD2DRD4DRD3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023172561-A1 | USE OF BLINK REFLEX FOR PARKINSON'S DISEASE RESPONSE MONITORING AND/OR TREATMENT SELECTION | Blinktbi, Inc. (US) | 2023-09-14 | — | — | WO | claimed |
| US-20230061743-A1 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS | WYETH LLC (US) | 2023-03-02 | — | — | US | claimed |
| CN-116554145-B | Aralkyl-4- (1H) indolylpiperazine derivative, preparation method and application thereof | 江苏恩华药业股份有限公司 | 2025-06-03 | — | — | CN | disclosed |
| US-12290510-B2 | Polyvalent derivatives of emoxypine | RIESNER VERWALTUNGS GMBH (DE) | 2025-05-06 | — | — | US | disclosed |
| WO-2024222837-A1 | TETRAHYDRONAPHTHYLPROPYLAMINOMETHYLPIPERIDINE ARYL (SULFONYL)AMIDE DERIVATIVE, PREPARATION METHOD, AND APPLICATION THEREOF | 江苏恩华药业股份有限公司 | 2024-10-31 | — | — | WO | disclosed |
| WO-2023172561-A1 | USE OF BLINK REFLEX FOR PARKINSON'S DISEASE RESPONSE MONITORING AND/OR TREATMENT SELECTION | Blinktbi, Inc. (US) | 2023-09-14 | — | — | WO | disclosed |
| CN-116554145-A | Aralkyl-4- (1H) indolylpiperazine derivative, preparation method and application thereof | 江苏恩华药业股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| US-20230061743-A1 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS | WYETH LLC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20230067811-A1 | MODULATING LYMPHATIC VESSELS IN NEUROLOGICAL DISEASE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2023-03-02 | — | — | US | disclosed |
| EP-4093426-A1 | MODULATING LYMPHATIC VESSELS IN NEUROLOGICAL DISEASE | University of Virginia Patent Foundation (US) | 2022-11-30 | — | — | EP | disclosed |
| US-20220096451-A1 | POLYVALENT DERIVATIVES OF EMOXYPINE | RIESNER VERWALTUNGS GMBH (DE) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230061743-A1 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS | ADCYAP1R1, ABCB11, SLC10A2 | DRD2 3240/4885DRD4 3941/4885DRD3 3367/4885 |
| US-20220096451-A1 | POLYVALENT DERIVATIVES OF EMOXYPINE | PARK7, SNCA, COMT | DRD2 110/4885DRD4 97/4885DRD3 169/4885 |
| US-12290510-B2 | Polyvalent derivatives of emoxypine | PARK7, SNCA, COMT | DRD2 110/4885DRD4 97/4885DRD3 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.